# Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age

> **NCT02576639** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 124 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** CNP520
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02576639
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-10
- **Primary completion:** 2016-03-11
- **Final completion:** 2016-03-11
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2017-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02576639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02576639, "Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT02576639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*